Physician profile
Gregory Paul Burkard
NPI 1467890590
$2,489.85
in general payments reported to CMS, 2019-2025
12 companies · $426 in 2025
The $426 reported for 2025 was more than what 76% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $421 · 2021: $847 · 2022: $196 · 2024: $245 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,342.40 | 2019-2025 | Simplex, Mako, 1788 |
| Nevro Corp. | $643.33 | 2019-2024 | Senza |
| Abbott Laboratories | $164.33 | 2019-2020 | |
| Boston Scientific Corporation | $115.40 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $60.36 | 2025 | |
| Bioventus LLC | $30.59 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Depuy Synthes Sales INC. | $25.48 | 2019 | |
| Globus Medical, INC. | $24.74 | 2025 | Senza |
| Trice Medical, INC. | $23.06 | 2025 | |
| Solventum Corporation | $21.00 | 2024 | Prevena |
| Kci USA, INC. | $20.64 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.52 | 2024 | Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Burkard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.